Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Global meltdown continues
Tue, 9 Aug 09:30 am

On the back of heavy selling pressure witnessed in the US stock markets in the previous trading session, Asian stock markets have taken the cue and opened the day on a very weak note. Stock markets in Hong Kong (down 5.6%), Indonesia (down 3.5%), Japan (down 3.7%) and South Korea (down 6.2%) are leading the pack of losers. The Indian stock markets have also opened the day with heavy losses. Stocks in the metal and technology space are facing severe selling pressure.

The BSE-Sensex is trading lower by around 406 points (2.4%), while the NSE-Nifty is down 121 points (2.4%). The midcap and smallcap stocks are in the negative as well with both the BSE Midcap and BSE Small cap indices down by 2.1% and 2.4% respectively. The rupee is trading at 45.34 to the US dollar.

Engineering stocks have opened the day on a weak note with L&T and BHEL in the red. Larsen & Toubro (L&T) has announced the first quarter results of financial year 2011-2012 (1QFY12). The company has reported 21.1% YoY and 12.0% YoY growth in sales and net profits respectively. Operating profits increased by 12.1% YoY for the quarter. However, operating margins declined by 0.9% to 11.9% during the quarter. The total order book increased by 26% YoY and stood at Rs 1,361 bn at the end of June 2011. The major orders during the quarter came from buildings and factories, infrastructure, power generation and minerals & metals among others. The company has also appointed Mr R. Shankar Raman as the new Chief Financial Officer.

Pharma stocks have opened the day on a weak note with Cipla, Ranbaxy and Lupin in the red. Lupin recalled one batch of Losartan Potassium Tablets. This medicine is used for treating high blood pressure. The recall took place from the US market as it was found that it exceeded permissible impurity level. The US Food and Drug Administration (USFDA) in its enforcement report said that Lupin was recalling a batch of 34,368 bottles as the drug did not meet specification for impurities at the nine-month stability station. The bottles that were manufactured in the Goa facility were getting expired in July 2012. The company in a statement said that the impurity was only found in a particular batch and as a precautionary measure the company has voluntarily recalled the batch.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Global meltdown continues". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.